Nexcella, a subsidiary of Immix Biopharma, announced that NXC-201 treatment continues to demonstrate 100% complete hematologic responses and 100% organ response rate – cardiac, renal, liver response – in a total of 8 AL amyloidosis patients. Additionally, Nexcella announced new positive safety data in relapsed/refractory multiple myeloma demonstrating outpatient CAR-T treatment potential. "In Multiple Myeloma, our 90% overall response rate continues to attract the attention of key opinion leaders globally. We have accumulated clinical data from 50 patients and counting," said Ilya Rachman, MD, PhD, Executive Chairman, Nexcella. "In AL Amyloidosis, our 100% complete response rate with 100% organ responses across cardiac, renal and liver organ systems fuels our continued excitement. NXC-201’s positive safety profile to-date could enable outpatient treatment in the thousands of U.S. community hospitals who today are unable to dose CAR-Ts."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on IMMX:
- Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank
- Nexcella Announces 50 Patients Already Treated with CAR-T NXC-201; Estimates 100-Patient Total Enrollment for U.S. Food and Drug Administration Approval BLA Submission
- Nexcella treats 50 patients with CAR-T NXC-201 in Phase 1b/2a trial
- Immix Biopharma initiated with a Buy at Roth MKM
- Immix’s Nexcella enters U.S. GMP manufacturing agreement for NXC-201 trial